Targeted Cancer Treatment Could be Possible Thanks to Insights into Cells’ Energy Supply
Credit: University of Sussex
Scientists have made a significant breakthrough in understanding how the molecular machines that produce key proteins in the power packs of cells are cleaned and maintained.
University of Sussex academics, working with colleagues around the globe on a project led by the Institute for Research in Biomedicine (IRB Barcelona), have shown that the enzyme EXD2 is critically involved in maintaining efficient protein production in mitochondria - the compartment responsible for making the energy required for cells to survive and replicate.
It is hoped the discovery, published in Nature Cell Biology, could be used to target tumours in cancer patients in a new way while also significantly adding to the understanding of the vital role mitochondria plays in the functioning of a healthy cell.
The research indicates that mitochondrial ribosomes, the cellular machines responsible for protein production in the mitochondria, interact with EXD2. Ribosomes read RNA messages to convert genetic information encoded by genes into the production of proteins that carry out the major functions within cells.
However, in cells these protein production machines must first be assembled and during this process they can prematurely bind to RNA molecules that “clog up” the works, preventing efficient protein production. It appears that a major role of EXD2 is to bind to these RNA molecules and cut them up to prevent this from happening.
Joana Silva, first author of the study and former PhD student of the Genomic Instability and Cancer Laboratory at IRB Barcelona, said: “EXD2 targets messenger RNA to keep the mitoribosome “clean” until it is mature and ready to generate proteins. In the absence of EXD2, cells are severely defective for mitochondrial protein production.”
Sussex’s role in the project, which involved scientists based at a host of institutions worldwide, was to identify what “flavour” of nucleic acid (DNA or RNA) EXD2 prefers to bind to and cut up.
Aidan Doherty, Professor of Biochemistry at Sussex’s Genome Damage and Stability Centre, said: “Our role in this incredibly complex project was to help pinpoint the molecular function of this enzyme. It was clear that EXD2 looked like a known DNA repair enzyme called WRN but we showed that, despite this similarity, it is preferentially involved in RNA, rather than DNA, metabolism. This project has helped further our understanding of the importance of maintaining efficient protein production in mitochondria, which are vitally important for supplying the energy required to enable cells to survive. It’s importance can be seen in the devastating impact of often fatal genetic disorders caused by malfunctioning mitochondria and in the growing global effort to correct these disorders.”
This study also revealed that EXD2 is critical in suppressing the generation of Reactive Oxygen Species (ROS), that can arise due to mitochondrial defects. Fruit flies lacking EXD2 showed increased ROS levels, delayed development and reduced fertility.
These findings run contrary to a previously published study claiming that EXD2 was involved in DNA repair processes within the nucleus of the cell.
Travis H. Stracker, head of the laboratory from the Genomic Instability and Cancer Laboratory at IRB Barcelona, said: “We have provided extensive evidence that EXD2 is a mitochondrial protein and that its main function is to facilitate the production of proteins in the mitochondria. The results highlight the complexity of mitochondrial protein production and demonstrate that many levels of regulation remain to be elucidated.”
Mitochondrial energy generation in tumors is gaining increased scrutiny in the fight against cancer, with some advocating the inhibition of protein production as a possible therapeutic target. It is hoped the this discovery could be useful in designing such strategies to target tumours in patients, while also adding to our understanding of the vital role that efficient mitochondrial protein synthesis plays in the functioning of healthy cells.
The full paper is available here.
This article has been republished from materials provided by University of Sussex. Note: material may have been edited for length and content. For further information, please contact the cited source.
Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous SclerosisNews
Addressing a critical issue for people with a genetic disorder called tuberous sclerosis complex (TSC), doctors reported that a skin cream containing rapamycin significantly reduced the disfiguring facial tumors affecting more than 90 percent of people with the condition.READ MORE
Calidi Biotherapeutics, Inc. Announces its Corporate Vision in Groundbreaking Cancer Drug DevelopmentNews
Calidi Biotherapeutics, Inc., formerly StemImmune, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, announced a focused effort to advance its oncolytic virus drug development.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE